MedPath

Protara Therapeutics

Protara Therapeutics logo
๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Public
Established
2017-01-01
Employees
27
Market Cap
$42.4M
Website
http://www.protaratx.com
Introduction

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

Phase 2
Recruiting
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
Biological: TARA-002
First Posted Date
2023-07-18
Last Posted Date
2024-11-05
Lead Sponsor
Protara Therapeutics
Target Recruit Count
127
Registration Number
NCT05951179
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Urology Associates of Denver, Lone Tree, Colorado, United States

๐Ÿ‡บ๐Ÿ‡ธ

Southern Urology, Lafayette, Louisiana, United States

๐Ÿ‡บ๐Ÿ‡ธ

Conrad Person Clinic, Memphis, Tennessee, United States

and more 13 locations

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Phase 2
Recruiting
Conditions
Lymphatic Malformation
Interventions
Biological: TARA-002
First Posted Date
2023-05-23
Last Posted Date
2024-12-27
Lead Sponsor
Protara Therapeutics
Target Recruit Count
38
Registration Number
NCT05871970
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Oregon Health & Science University, Portland, Oregon, United States

๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital of Alabama, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Arkansas Children's Hospital/UAMS, Little Rock, Arkansas, United States

and more 7 locations

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Phase 1
Completed
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
Biological: TARA-002
First Posted Date
2021-10-20
Last Posted Date
2024-11-05
Lead Sponsor
Protara Therapeutics
Target Recruit Count
10
Registration Number
NCT05085990
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Chesapeake Urology Research Associates, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

Urology Associates PC, Nashville, Tennessee, United States

๐Ÿ‡บ๐Ÿ‡ธ

Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

and more 6 locations

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Phase 1
Active, not recruiting
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
Biological: TARA-002
First Posted Date
2021-10-20
Last Posted Date
2024-08-09
Lead Sponsor
Protara Therapeutics
Target Recruit Count
12
Registration Number
NCT05085977
Locations
๐Ÿ‡บ๐Ÿ‡ธ

New Jersey Urology, Mount Laurel, New Jersey, United States

๐Ÿ‡บ๐Ÿ‡ธ

Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

๐Ÿ‡ฒ๐Ÿ‡ฉ

PMSI Republican Clinical Hospital "T. Mosneaga," ARENSIA Exploratory Medicine Phase I Unit, Chisinau, Moldova, Republic of

and more 10 locations

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

Completed
Conditions
Intestinal Failure-associated Liver Disease
First Posted Date
2021-08-18
Last Posted Date
2023-10-03
Lead Sponsor
Protara Therapeutics
Target Recruit Count
80
Registration Number
NCT05011370
Locations
๐Ÿ‡บ๐Ÿ‡ธ

IHS Health, Kissimmee, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

The University of Chicago, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Virginia Commonwealth University, Richmond, Virginia, United States

and more 12 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath